Tumor necrosis factor inhibitors are associated with a decreased risk of COVID‐19‐associated hospitalization in patients with psoriasis—A population‐based cohort study

The risk of coronavirus disease 2019 (COVID‐19) and its complications among patients with psoriasis treated by tumor necrosis factor inhibitors (TNFis) remains to be decisively delineated. We aimed to assess the risk of COVID‐19 infection, COVID‐19‐associated hospitalization, and mortality among Isr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kridin, Khalaf, Schonmann, Yochai, Damiani, Giovanni, Peretz, Avi, Onn, Erez, Bitan, Dana Tzur, Cohen, Arnon D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209905/
https://www.ncbi.nlm.nih.gov/pubmed/34033207
http://dx.doi.org/10.1111/dth.15003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209905/
https://www.ncbi.nlm.nih.gov/pubmed/34033207
http://dx.doi.org/10.1111/dth.15003

Ejemplares similares